<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589326</url>
  </required_header>
  <id_info>
    <org_study_id>Ponatinib-3001</org_study_id>
    <secondary_id>2018-000397-30</secondary_id>
    <secondary_id>U1111-1206-2370</secondary_id>
    <secondary_id>HC6-24-c220300</secondary_id>
    <nct_id>NCT03589326</nct_id>
  </id_info>
  <brief_title>A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute&#xD;
      lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib.&#xD;
&#xD;
      The main aim of this study is to compare the number of participants on each treatment that&#xD;
      show no signs of disease.&#xD;
&#xD;
      Participants will take tablets of either ponatinib or imatinib at the same time each day&#xD;
      combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue&#xD;
      with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation&#xD;
      criteria from the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called ponatinib. Ponatinib is being tested to treat&#xD;
      people who have newly diagnosed Ph+ ALL. This study will look at the efficacy of ponatinib in&#xD;
      participants in addition to standard care.&#xD;
&#xD;
      The study will enroll approximately 230 participants. Participants will be randomized in a&#xD;
      2:1 ratio to receive oral ponatinib or imatinib (Cohort A and Cohort B, respectively) daily&#xD;
      throughout the study.&#xD;
&#xD;
      All participants will be asked to take ponatinib or imatinib at the same time each day with&#xD;
      reduced-intensity chemotherapy in induction phase (Cycles 1 to 3), consolidation phase&#xD;
      (Cycles 4 to 9) and maintenance phase (Cycles 10 to 20). At the end of the 20 cycles,&#xD;
      participants will remain on ponatinib or imatinib (administered as a single agent). The dose&#xD;
      of ponatinib in consolidation and maintenance phase will start with the last dose given in&#xD;
      the previous phase. The dose can be modified based on MRD-negative CR results.&#xD;
&#xD;
      This multi-center trial will be conducted in Argentina, Australia, Austria, Belarus, Brazil,&#xD;
      Bulgaria, Canada, Chile, France, Mexico, Greece, Italy, Japan, Korea, Republic Of, Poland,&#xD;
      Romania, Russia, Spain, Taiwan, Province Of China, Turkey, Finland and the United States.&#xD;
      Participants including those who achieve a clinical response, may receive study drug until&#xD;
      they are deceased, have failed to achieve the primary endpoint, have experienced relapse from&#xD;
      CR or have progressive disease, have an unacceptable toxicity, have withdrawn consent, have&#xD;
      proceeded to HSCT, or until the sponsor terminates the study, whichever occurs first. After&#xD;
      disease progression, all participants will be contacted every 3 months for survival&#xD;
      follow-up. Participants will be followed until completion of the study or until the&#xD;
      participant's death has been reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>It is an open-label trial, therefore investigators and participants are unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Minimal Residual Disease (MRD)-Negative Complete Remission (CR)</measure>
    <time_frame>From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length is equal to [=] 28 days)</time_frame>
    <description>MRD-negative CR is achieved when a participant meets the criteria for both MRD negativity and CR. MRD-negativity: less than or equal to (&lt;=) 0.01 percent (%) breakpoint cluster region-Abelson (BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in complementary deoxyribonucleic acid (cDNA) with greater than or equal to (&gt;=) 10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and less than (&lt;) 5% blasts in the bone marrow (BM). 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (central nervous system [CNS] involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. Absolute neutrophil count (ANC) greater than (&gt;) 1000 per micro liter (/mcL) (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Baseline up to approximately 3 to 6 years</time_frame>
    <description>EFS is defined as the dates of randomization until death due to any cause or failure to achieve CR by end of induction or relapse from CR. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and less than (&lt;) 5% blasts in the bone marrow (BM). 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (central nervous system [CNS] involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. Absolute neutrophil count (ANC) greater than (&gt;) 1000 per micro liter (/mcL) (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L).Relapse from CR: reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR and Incomplete Complete Remission (CRi)</measure>
    <time_frame>End of Cycle 1 (approximately 1 month), Cycle 2 (approximately 2 months), Cycle 3 (approximately 3 months), and Cycle 9 (approximately 9 months) (Cycle length= 28 days)</time_frame>
    <description>CR is defined as meeting all the following for at least 4 weeks (that is, no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). CRi is defined as hematologic complete remission with incomplete hematologic recovery and meeting all criteria for CR except platelet count and/or ANC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Molecular Response</measure>
    <time_frame>End of Cycle 1 (approximately 1 month), Cycle 2 (approximately 2 months), Cycle 3 (approximately 3 months), and Cycle 9 (approximately 9 months) (Cycle length= 28 days)</time_frame>
    <description>Molecule response is assessed by 3-Log Reduction (MR3), Molecular Response 4-Log Reduction (MR4) and Molecular Response 4.5-Log Reduction (MR4.5). MR3 is defined as molecular response 3-log reduction (&lt;=0.1% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=1000 ABL1 transcripts. MR4 is defined as molecular response 4-log reduction (&lt;=0.01% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. MR4.5 is defined as Molecular response 4.5-log reduction (&lt;=0.0032% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=32,000 ABL1 transcripts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Primary Induction Failure (PIF)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>PIF is defined as participants who received treatment for ALL but never achieved CR or CRi by the end of induction. PIF is not limited by the number of unsuccessful treatments; this disease status only applies to recipients who have never been in CR or CRi. CR is defined as meeting all the following for at least 4 weeks (that is no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). CRi is defined as hematologic complete remission with incomplete hematologic recovery and meeting all criteria for CR except platelet count and/or ANC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Overall Response Rate (ORR)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>ORR is defined as CR + CRi by end of induction. CR is defined as meeting all the following for at least 4 weeks (that is no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). CRi is defined as hematologic complete remission with incomplete hematologic recovery and meeting all criteria for CR except platelet count and/or ANC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of MRD-Negative CR</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>MRD is defined as the percentage of participants achieving CR who are MRD-negative at multiple intervals after end of induction. MRD negativity: &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. Relapse from CR: Reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MRD-Negative CR</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>Duration of MRD-negative CR is defined as interval between the first assessment at which the criteria for MRD-negative CR are met until the earliest date at which loss of MRD negativity or relapse from CR occurs. MRD negativity (MR4): &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. CR is defined as meeting all the following for at least 4 weeks (that is, no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). Relapse from CR: Reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>Duration of CR is defined as interval between the first assessment at which the criteria for CR are met until the earliest date at which relapse from CR occurs. CR is defined as meeting all the following for at least 4 weeks (that is no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). Relapse from CR: Reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to treatment failure is defined as time to end of study randomized treatment (except for hematopoietic stem cell transplantation [HSCT] without loss of MRD-negative CR) due to safety and efficacy reasons. MRD-negative CR is achieved when a participant meets the criteria for both MRD negativity and CR. MRD-negativity: &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MR4.5</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>Duration of MR4.5 is defined as interval between the first assessment at which the criteria for MR4.5 are met until the earliest date at which loss of MR4.5 occurs. MR4.5 is molecular response 4.5-log reduction (&lt;=0.0032% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=32,000 ABL1 transcripts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of On-Study Participants with Overall Survival (OS)</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>On-study participants with or without HSCT will be evaluated. OS is defined as interval between randomization and death due to any cause, censored at the last contact date when the participant was alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of On-Study Participants with Relapse From CR</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>On-study participants with or without HSCT will be evaluated. Relapse from CR is defined as reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 3 to 6 years</time_frame>
    <description>OS is defined as interval between the randomization and death due to any cause, censored at the last contact date when the participant was alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)</condition>
  <arm_group>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ponatinib 30 mg, tablets, orally, once daily (QD), with vincristine 1.4 mg/m^2 intravenous(IV), on Days 1 and 14 and dexamethasone 40 mg(&lt;60 years [yrs]) and 20 mg (&gt;=60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 for up to 3 cycles (each cycle will be of 28-days) in induction phase followed by ponatinib last dose of induction phase tablets, orally, QD, with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour IV infusion (&lt;60 yrs) and 250 mg/m^2 every 12 hours (&gt;=60 yrs), IV on Days 1, 3, and 5 of Cycles 2, 4, and 6, (cytarabine dose will be reduced/ discontinued in case of impaired renal function) and methotrexate, 1000 mg/m^2 (&lt;60 yrs) and 250 mg/m^2 (&gt;=60 yrs), IV infusion, on Day 1 of cycles 1, 3, and 5 in consolidation phase followed by ponatinib last dose of consolidation phase, tablets, orally, QD, with vincristine 1.4 mg/m^2, IV, on Day 1 and prednisone 200 mg (&lt;60 yrs), 100 mg (&gt;=60-69 yrs) and 50 mg(&gt;=70 yrs) on Days 1 to 5 for up to 11 cycles in maintenance phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib 600 mg,tablets, orally,QD,along with vincristine 1.4 mg/m^2 (max 2 mg),IV,on Days 1 and 14 and dexamethasone 40 mg (&lt;60 yrs) and 20 mg (≥60 yrs),orally,once on Days 1 through 4 and Days 11 through 14 in each 28-day cycle up to 3 cycles in induction phase followed by imatinib 600 mg,tablets,orally,QD, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (&lt;60 yrs) and 250 mg/m^2 every 12 hours (≥60 yrs), IV on Days 1,3, and 5 of each 28-day even cycles (Cycles 2,4,and 6), (cytarabine dose reduced/discontinued for participant with impaired renal function) and methotrexate, 1000 mg/m^2 (&lt;60 yrs) and 250 mg/m^2 (≥60 yrs),IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1,3,and 5) in consolidation phase followed by imatinib 600 mg,tablets,orally,QD, along with vincristine 1.4 mg/m^2 (max 2 mg),IV,on Day 1 and prednisone 200 mg (&lt;60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each 28-day cycle up to 11 cycles in maintenance phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Ponatinib Tablets.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <other_name>Iclusig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib Tablets.</description>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine IV injection.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone Tablets.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine IV infusion.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate IV infusion.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone Tablets.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as&#xD;
             defined by the 2017 national comprehensive cancer network (NCCN) guidelines.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of &lt;=2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With a history or current diagnosis of chronic phase, accelerated phase, or blast&#xD;
             phase chronic myeloid leukemia (CML).&#xD;
&#xD;
          2. Prior/current treatment with any systemic anticancer therapy (including but not&#xD;
             limited to any tyrosine kinase inhibitor [TKI]) and/or radiotherapy for ALL, with the&#xD;
             exception of an optional prephase therapy or chemotherapy induction (no more than 1&#xD;
             cycle), which should be discussed with the sponsor's medical monitor/designee.&#xD;
&#xD;
          3. Currently taking drugs that are known to have a risk of causing prolonged corrected QT&#xD;
             (QTc) or torsades de pointes (TdP) (unless these can be changed to acceptable&#xD;
             alternatives or discontinued).&#xD;
&#xD;
          4. Taking any medications or herbal supplements that are known to be strong inhibitors or&#xD;
             strong inducers of cytochrome P450 (CYP)3A4 within at least 14 days before the first&#xD;
             dose of study drug.&#xD;
&#xD;
          5. Uncontrolled active serious infection that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol.&#xD;
&#xD;
          6. Major surgery within 28 days before randomization (minor surgical procedures such as&#xD;
             catheter placement or BM biopsy are not exclusionary criteria).&#xD;
&#xD;
          7. Known human immunodeficiency virus (HIV) seropositivity, known active hepatitis B or C&#xD;
             infection.&#xD;
&#xD;
          8. History of acute pancreatitis within 1 year of study screening or history of chronic&#xD;
             pancreatitis.&#xD;
&#xD;
          9. Uncontrolled hypertriglyceridemia (triglycerides &gt;450 milligram per deciliter&#xD;
             [mg/dL]).&#xD;
&#xD;
         10. Diagnosed and treated for another malignancy within 5 years before randomization or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type&#xD;
             are not excluded if they have undergone complete resection.&#xD;
&#xD;
         11. History or presence of clinically relevant CNS pathology such as epilepsy, childhood&#xD;
             or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia,&#xD;
             Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.&#xD;
&#xD;
         12. Clinical manifestations of CNS or extramedullary involvement with ALL other than&#xD;
             lymphadenopathy or hepatosplenomegaly.&#xD;
&#xD;
         13. Autoimmune disease with potential CNS involvement.&#xD;
&#xD;
         14. Known significant neuropathy of Grade &gt;=2 severity.&#xD;
&#xD;
         15. Clinically significant, uncontrolled, or active cardiovascular, cerebrovascular, or&#xD;
             peripheral vascular disease, or history of or active venous thrombotic/embolic event&#xD;
             (VTE) disease.&#xD;
&#xD;
         16. Have a significant bleeding disorder unrelated to ALL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Call center</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>205-934-9591</phone>
      <email>pvachhani@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Pankit Vachhani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope - Duarte</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>626-256-4673</phone>
      <email>ialdoss@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Aldoss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>310-206-6909</phone>
      <email>pyoung@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>706-721-6744</phone>
      <email>vkota@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Vamsi Kota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>317-274-3590</phone>
      <email>hkonig@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Heiko Konig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood &amp; Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>317-528-5500</phone>
      <email>lakard@ibmtindy.com</email>
    </contact>
    <investigator>
      <last_name>Luke Akard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>585-957-4381</phone>
      <email>hmale@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Male</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>410-328-8708</phone>
      <email>mbaer@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Baer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>551-996-3049</phone>
      <email>james.mccloskey@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>James McCloskey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>716-845-3544</phone>
      <email>eunice.wang@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Eunice Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>516-734-8866</phone>
      <email>cghiuzeli@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Ghiuzeli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>631-444-3577</phone>
      <email>michael.schuster@stonybrook.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>503-494-8211</phone>
      <email>leonard@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Leonard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>713-563-4553</phone>
      <email>ejabbour@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Elias Jabbour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>210-575-3817</phone>
      <email>jose.cruz@mhshealth.com</email>
    </contact>
    <investigator>
      <last_name>Jose Carlos Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+5401149590348</phone>
      <email>dorotea.fantl@hospitalitaliano.org.ar</email>
    </contact>
    <investigator>
      <last_name>Dorotea Beatriz Eugenia Fantl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+543514269285</phone>
      <email>gjarchum@sanatorioallende.com</email>
    </contact>
    <investigator>
      <last_name>Gustavo Jarchum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro Medico de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5014KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+543514688894</phone>
      <email>jgarcia@hospitalprivadosa.com.ar</email>
    </contact>
    <investigator>
      <last_name>Juan Jose Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61299264393</phone>
      <email>matthew.greenwood@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Matthew Greenwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61390949502</phone>
      <email>a.schwarer@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Schwarer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61408341855</phone>
      <email>pasq.fedele@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pasquale Fedele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61430509338</phone>
      <email>s.fleming2@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Shaun Fleming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz Elisabethinen</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4373276764400</phone>
      <email>sigrid.machherndl-spandl@ordensklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Sigrid Machherndl-Spandl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus Wiener Gebietskrankenkasse</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4369917979717</phone>
      <email>thamer.sliwa@wgkk.at</email>
    </contact>
    <investigator>
      <last_name>Thamer Sliwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Fuer Innere Medizin I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43014040044570</phone>
      <email>alexander.hauswirth@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Alexander Hauswirth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican Research Centre for Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <state>Homyelrskaya</state>
        <zip>246040</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+375232378092</phone>
      <email>novikdk@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Dzmitry Novik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minsk Scientific and Practical Center of Surgery, Transplantation and Haematology</name>
      <address>
        <city>Minsk</city>
        <zip>220045</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3758172727091</phone>
      <email>ponatinib.mspc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anatoly Uss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Center of Children's Oncology, Hematology and Immunology</name>
      <address>
        <city>Minsk</city>
        <zip>223053</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3758172024222</phone>
      <email>aleinikova2004@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Olga Aleinikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Rafael-Monte Tabor</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+557132816965</phone>
      <email>marcohemato@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Marco Aurelio de Araujo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eurolatino Juiz de Fora Pesquisas Medicas</name>
      <address>
        <city>Juiz De Fora</city>
        <state>Minas Gerais</state>
        <zip>36033-318</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+553230254050</phone>
      <email>andregalassi@eurolatinomr.com</email>
    </contact>
    <investigator>
      <last_name>Angelo Atalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+554133615195</phone>
      <email>jf.cordeirocamargo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Johnny Francisco Camargo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital da Cidade</name>
      <address>
        <city>Passo Fundo</city>
        <state>RIO Grande DO SUL</state>
        <zip>99010-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+555433164064</phone>
      <email>denisedeal@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Denise Almeida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+555132148143</phone>
      <email>fogliattopesquisa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laura Maria Fogliatto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hemocentro Campinas Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>SAO Paulo</state>
        <zip>130383-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+551935218740</phone>
      <email>kborgia@unicamp.br</email>
    </contact>
    <investigator>
      <last_name>Katia Barbosa Pagnano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacao Doutor Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>SAO Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+5514360213971526</phone>
      <email>pesquisafac.edersonmattos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ederson De Mattos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Riberao Preto da Universidade de Sao Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SAO Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+551636022956</phone>
      <email>lorenafigdo@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Lorena Pontes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEMORIO Instituto Estadual de Hematologia</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+5521233286112141</phone>
      <email>diretor.tecnico@hemorio.rj.gov.br</email>
    </contact>
    <investigator>
      <last_name>Patricia Moura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+551145737631</phone>
      <email>vanderson.rocha@hc.fm.usp.br</email>
    </contact>
    <investigator>
      <last_name>Vanderson Rocha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacao Antonio Prudente - A.C.Camargo Cancer Center</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+551121895017</phone>
      <email>jayr.filho@accamargo.org.br</email>
    </contact>
    <investigator>
      <last_name>Jayr Schmidt Filho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Saint Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <state>Sofiya</state>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+359024034838</phone>
      <email>aradinoff@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Atanas Radinoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+359064886335</phone>
      <email>ntzvetkov50@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nikolay Tzvetkov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>855 West 12th Avenue</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>1 (604) 875-4863</phone>
      <email>ymourad@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Yasser Mourad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>1 (204) 787-2197</phone>
      <email>kpaulson@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Kristjan Paulson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>1 (613) 737-8899 ext: 71284</phone>
      <email>jfulcher@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Jill Fulcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Charles-LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>1 (450) 466-5000 ext: 3226</phone>
      <email>pierre.desjardins@rrsss16.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Desjardins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>1 (514) 252-3400</phone>
      <email>juliebergeron.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Julie Bergeron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613703904030</phone>
      <email>jnyinqingsong@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingsong Yin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University/Suzhou First People's Hospital</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8651267783686</phone>
      <email>qiuhuiying@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Huiying Qiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8615843073208</phone>
      <email>sujung1963@163.com</email>
    </contact>
    <investigator>
      <last_name>Sujun Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86057187236702</phone>
      <email>jiej0503@163.com</email>
    </contact>
    <investigator>
      <last_name>Jie Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital of CAMS &amp; PUMC</name>
      <address>
        <city>Tianjin</city>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613821389157</phone>
      <email>wangjx@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Jianxiang Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsingin ja Uudenmaan sairaanhoitopiiri</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3580947172338</phone>
      <email>kimmo.porkka@helsinki.fi</email>
    </contact>
    <investigator>
      <last_name>Kimmo Porkka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulun Yliopistollinen Sairaala</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>timo.siitonen@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Timo Siitonen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+35823130169</phone>
      <email>urpu.salmenniemi@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Urpu Salmenniemi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <state>Ile-de-france</state>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33139639133</phone>
      <email>phrousselot@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Rousselot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Ile-de-france</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33142499643</phone>
      <email>herve.dombret@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Dombret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse Oncopole</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <state>Midi-pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33531156269</phone>
      <email>huguet.francoise@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Francoise Huguet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <state>PAYS DE LA Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33241354475</phone>
      <email>mahunault@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde Hunault-Berger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <state>Rhone-alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33478862240</phone>
      <email>xavier.thomas@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evaggelismos General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302107201000</phone>
      <email>mbouzani@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria Bouzani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens G. Gennimatas</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302107768186</phone>
      <email>tpmarin1@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Theodoros Marinakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens Attikon</name>
      <address>
        <city>Chaidari</city>
        <state>Attica</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302105832307</phone>
      <email>vaspappa@med.uoa.gr</email>
    </contact>
    <investigator>
      <last_name>Vassiliki Pappa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion Panepistimiako Geniko Nosokomeio Irakleiou</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302813402805</phone>
      <email>epapadak@med.uoc.gr</email>
    </contact>
    <investigator>
      <last_name>Eleni Papadaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki George Papanikolaou</name>
      <address>
        <city>Thessaloniki</city>
        <state>Macedoni</state>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302313307522</phone>
      <email>luizana6@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chrysavgi Lalayanni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras Panagia I Voithia</name>
      <address>
        <city>Patra</city>
        <state>Peloponnese</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302613603255</phone>
      <email>argiris.symeonidis@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Argiris Symeonidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3021065970346</phone>
      <email>gvasilop@bioacademy.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Vassilopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli-cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390516364077</phone>
      <email>giovanni.martinelli@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Martinelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+39105554316</phone>
      <email>germana.beltrami@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Germana Beltrami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390392339553</phone>
      <email>carlo.gambacorti@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Gambacorti Passerini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Reggio Nella Emilia</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390522296822</phone>
      <email>annalisa.imovilli@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Imovilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390419657362</phone>
      <email>renato.bassan@aulss3.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Renato Bassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390516363827</phone>
      <email>cristina.papayannidis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Papayannidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390832661923</phone>
      <email>direnzo.ematolecce@libero.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390226431</phone>
      <email>ciceri.clinicaltrials@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+0594225570</phone>
      <email>mario.luppi@unimore.it</email>
    </contact>
    <investigator>
      <last_name>Mario Luppi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390916802023</phone>
      <email>francesco.fabbiano@villasofia.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Fabbiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda USL della Romagna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390544285734</phone>
      <email>francesco.lanza@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Lanza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Ematologia Policlinico Umberto I Universita Sapienza di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3906441639824</phone>
      <email>chiaretti@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Sabina Chiaretti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390630155300</phone>
      <email>simona.sica@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Simona Sica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81783825111</phone>
      <email>jyuda@east.ncc.go.jp</email>
    </contact>
    <investigator>
      <last_name>Junichiro Yuda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aiiku Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>064-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+810115632211</phone>
      <email>t-kondoh@med.hokudai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Kondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara City</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81463931121</phone>
      <email>moni5@mac.com</email>
    </contact>
    <investigator>
      <last_name>Makoto Onizuka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81862237151</phone>
    </contact>
    <investigator>
      <last_name>Noboru Asada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba Aoba Municipal Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81432271131</phone>
    </contact>
    <investigator>
      <last_name>Akira Yokota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81245471111</phone>
      <email>ikezoet@fmu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takayuki Ikezoe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+820312497114</phone>
      <email>jakimapril@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeong A Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82534205114</phone>
      <email>knuhhema@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sang-Kyun Sohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82532587713</phone>
      <email>dyr1160@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Young Rok Do</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+826325018605</phone>
      <email>jykwak@chonbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae-Yong Kwak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82518908849</phone>
      <email>wonsik112@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Won Sik Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82 51 797 0064</phone>
      <email>sunhyeko@inje.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sun-Hye Ko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82536204683</phone>
      <email>kmk21c@medical.yu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Min Kyoung Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82536504042</phone>
      <email>sunghwa@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sung Hwa Bae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82220720834</phone>
      <email>kim_dajung@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Inho Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82226505061</phone>
      <email>yeungchul@ewha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yeung-Chul Mun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+528183486136</phone>
      <email>dgomezalmaguer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Gomez Almaguer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48717842525</phone>
      <email>a.czyz@umed.wroc.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Czyz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Number 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48600023009</phone>
      <email>togromek@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tomasz Gromek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48124247751</phone>
      <email>sachatom@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tomasz Sacha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48585844357</phone>
      <email>wpre@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Witold Prejzner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie - Oddzial w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48322788523</phone>
      <email>sebastian.giebel@io.gliwice.pl</email>
    </contact>
    <investigator>
      <last_name>Sebastian Giebel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurs</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48602120684</phone>
      <email>janusz.halka@poliklinika.net</email>
    </contact>
    <investigator>
      <last_name>Janusz Halka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal de Urgenta Timisoara</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300021</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+40256432886</phone>
      <email>ionitahortensia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hortensia Ionita</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+40745637403</phone>
      <email>73mihaela.popescu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mihaela Popescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Bucuresti</name>
      <address>
        <city>Bucuresti</city>
        <zip>50098</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+40726329384</phone>
      <email>horiabum@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Horia Bumbea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+40740157774</phone>
      <email>angdascalescu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Angela Smaranda Dascalescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital named after Vikentiy Vikentyevich Veresaev</name>
      <address>
        <city>Moscow</city>
        <state>Moscow CITY</state>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79216365472</phone>
      <email>shuvaev77@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vasily Shuvaev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+783433511697</phone>
      <email>kts@okb1.ru</email>
    </contact>
    <investigator>
      <last_name>Tatyana Konstantinova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 52 of the Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+74991961788</phone>
      <email>misyurina_elena@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Misyurina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Center for Hematology, Dept. of Hematology/Oncology and BMT</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+784956122123</phone>
      <email>elenap@blood.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Parovichnikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Almazov Federal North-West Medical Research Centre of Department of Health of Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+78127023765</phone>
      <email>lomelza@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elza Lomaia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia Badalona - Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Cataluna</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34934978417</phone>
      <email>jribera@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Jose-Maria Ribera Santasusana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+9374661004897</phone>
      <email>pbarba@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Pere Barba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34914269826</phone>
      <email>silvia.monsalvo@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Silvia Monsalvo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34923260402</phone>
      <email>jmhr@usal.es</email>
    </contact>
    <investigator>
      <last_name>Jesus Maria Hernandez Rivas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34961244925</phone>
      <email>montesinos_pau@gva.es</email>
    </contact>
    <investigator>
      <last_name>Pau Montesinos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien City</city>
        <state>Hualien</state>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8863856182517602</phone>
      <email>kevinlcc1234@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chi-Cheng Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Taichung CITY</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8864220521215050</phone>
      <email>lybai6@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li-Yuan Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <state>Tainan CITY</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+886623535354559</phone>
      <email>teresa@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Tsai-Yun Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+9005334330694</phone>
      <email>guvenc.birol@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Birol Guvenc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tp Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+9003124663577</phone>
      <email>arslan@medicine.ankara.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Onder Arslan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ponatinib</keyword>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Bcr-Abl Tyrosine Kinase</keyword>
  <keyword>Bcr-abl fusion proteins</keyword>
  <keyword>Iclusig</keyword>
  <keyword>Gleevec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

